Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 Shares

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $35.01, for a total transaction of $350,100.00. Following the completion of the transaction, the insider directly owned 129,763 shares in the company, valued at $4,543,002.63. This represents a 7.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Schoenberg also recently made the following trade(s):

• On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The stock was sold at an average price of $27.30, for a total value of $142,560.60.

Urogen Pharma Trading Up 0.8%

Shares of URGN opened at $35.42 on Thursday. Urogen Pharma has a 12 month low of $12.73 and a 12 month high of $36.08. The stock has a fifty day moving average price of $27.97 and a 200-day moving average price of $23.20. The firm has a market cap of $1.73 billion, a PE ratio of -12.88 and a beta of 1.59.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $50.96 million during the quarter, compared to analyst estimates of $44.83 million. As a group, research analysts forecast that Urogen Pharma will post -0.98 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group upgraded Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. HC Wainwright reiterated a “buy” rating and issued a $45.00 target price on shares of Urogen Pharma in a research note on Wednesday, June 3rd. D. Boral Capital reissued a “buy” rating and set a $33.00 target price on shares of Urogen Pharma in a research report on Tuesday, March 31st. Oppenheimer restated an “outperform” rating on shares of Urogen Pharma in a research note on Tuesday, June 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Urogen Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

Institutional Trading of Urogen Pharma

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its holdings in shares of Urogen Pharma by 36.9% during the third quarter. JPMorgan Chase & Co. now owns 534,545 shares of the company’s stock worth $10,664,000 after purchasing an additional 144,181 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in Urogen Pharma by 148.4% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 161,924 shares of the company’s stock valued at $3,792,000 after purchasing an additional 96,741 shares during the period. SG Americas Securities LLC boosted its holdings in Urogen Pharma by 19.0% in the fourth quarter. SG Americas Securities LLC now owns 1,377,647 shares of the company’s stock valued at $32,264,000 after purchasing an additional 220,264 shares during the last quarter. Elmind Capital LP purchased a new stake in Urogen Pharma in the fourth quarter valued at $2,342,000. Finally, Rice Hall James & Associates LLC grew its position in Urogen Pharma by 8.8% during the 4th quarter. Rice Hall James & Associates LLC now owns 281,876 shares of the company’s stock worth $6,602,000 after purchasing an additional 22,733 shares during the period. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.